**Name of Journal:** *World Journal of Clinical Cases*

**Manuscript NO:** 82385

**Manuscript Type:** CASE REPORT

**Late-onset mitochondrial encephalomyopathy with lactic acidosis and stroke-like episodes syndrome with mitochondrial DNA 3243A>G mutation masquerading as autoimmune encephalitis: A case report**

Wang JW *et al*. Atypical clinical features of MELAS

Jian-Wei Wang, Xiao-Bo Yuan, Hong-Fang Chen

**Jian-Wei Wang, Hong-Fang Chen,** Department of Neurology, The Affiliated Jinhua Hospital, Zhejiang University School of Medicine, Jinhua 321000, Zhejiang Province, China

**Xiao-Bo Yuan,** Department of Neurology, The First People's Hospital of Yongkang, Jinhua 321300, Zhejiang Province, China

**Author contributions:** Chen HF and Yuan XB played a major role in the acquisition of data; Chen HF and Wang JW analyzed and interpreted the patient data regarding a series of MRI images; Chen HF and Yuan XB were major contributors in writing the manuscript; all authors have read and approved the final manuscript.

**Supported by** the Science and Technology Plan of Jinhua City, No. 2020-3-026.

**Corresponding author: Hong-Fang Chen, MM, Chief Physician, Director,** Department of Neurology, The Affiliated Jinhua Hospital, Zhejiang University School of Medicine, No. 356 Renmin East Road, Jinhua 321000, Zhejiang Province, China. jhchf894@163.com

**Received:** January 3, 2023

**Revised:** February 27, 2023

**Accepted:** April 7, 2023

**Published online:**

**Abstract**

BACKGROUND

Here, we present a unique case of mitochondrial encephalomyopathy with lactic acidosis and stroke-like episodes (MELAS) syndrome, which initially appeared to be autoimmune encephalitis and was ultimately confirmed as MELAS with the mitochondrial DNA 3243A>G mutation.

CASE SUMMARY

A 58-year-old female presented with acute-onset speech impediment and auditory hallucinations, symmetrical bitemporal lobe abnormalities, clinical and laboratory findings, and a lack of relevant prodromal history, which suggested diagnosis of autoimmune encephalitis. Further work-up, in conjunction with the patient’s medical history, family history, and lactate peak on brain lesions on magnetic resonance imaging, suggested a mitochondrial disorder. Mitochondrial genome analysis revealed the m.3243A>G variant in the *MT-TL1* gene, which led to a diagnosis of MELAS syndrome.

CONCLUSION

This case underscores the importance of considering MELAS as a potential cause of autoimmune encephalitis even if patients are over 40 years of age and symptoms and signs are atypical for MELAS syndrome.

**Key Words:** MELAS; Mitochondrial DNA mutation; Encephalitis; Case report

Wang JW, Yuan XB, Chen HF. Late-onset mitochondrial encephalomyopathy with lactic acidosis and stroke-like episodes syndrome with mitochondrial DNA 3243A>G mutation masquerading as autoimmune encephalitis: A case report. *World J Clin Cases* 2023; In press

**Core Tip:** Mitochondrial encephalomyopathy with lactic acidosis and stroke-like episodes (MELAS) syndrome is a multimitochondrial disease caused by DNA mutations and respiratory chain defects that is frequently misdiagnosed. Here, we describe a 58-year-old patient with MELAS syndrome who initially presented with acute cognitive impairment, tinnitus, and headache and was subsequently misdiagnosed with autoimmune encephalitis. The final diagnosis was based on MELAS mutation blood tests and magnetic resonance imaging results. The patient was treated with appropriate medication and gradually improved. This case shows that MELAS syndrome should be diagnosed only after other causes, including autoimmune encephalitis, have been ruled out and the atypical clinical features of MELAS syndrome, such as older age of onset, have been considered.

**INTRODUCTION**

Mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes (MELAS) syndrome is a multisystemic mitochondrial disorder[1]. MELAS is caused by mutations in mitochondrial DNA and subsequent respiratory chain deficiency[2]. In most cases, MELAS syndrome is characterized by severe aches, stroke-like episodes, short stature, sensorineural deafness, cognitive decline, and exercise intolerance. Conversely, hypertrophic cardiomyopathy, ataxia, ophthalmoplegia, and diabetes mellitus are rare features of MELAS[3,4]. MELAS syndrome presenting with the features of acute encephalitis is rare and has been described in only a few case reports[5,6]. Among these few cases, nonviral encephalitis is even rarer and may therefore pose a diagnostic challenge. Of note, the above clinical manifestations generally occur before the age of 40[5].

Here, we report the unique case of a 58-year-old female whose condition initially appeared to be autoimmune encephalitis and who was ultimately diagnosed with MELAS syndrome in the presence of the m.3243A>G mutation.

**CASE PRESENTATION**

***Chief complaints***

Speech impediment and auditory hallucination, accompanied by tinnitus and headache for 3 d.

***History of present illness***

A 58-year-old female presented with sudden cognitive dysfunction, auditory hallucinations, nonsensical behavior, inability to communicate normally with others, and complaints of headache and tinnitus. The patient had no fever, seizures, or consciousness disturbance.

***History of past illness***

The patient had a history of bilateral hearing loss.

***Personal and family history***

The patient had no history of mental retardation or cognitive decline up to the time of her acute illness. Moreover, the patient denied a family history of neuromuscular disease, encephalitis, or mitochondrial disease.

***Physical examination***

On admission, the patient's height was 158 cm, and her weight was 45 kg. On physical examination, her body temperature was 36.5 °C and a history of previous infection and fever were denied. Chest auscultation revealed normal respiratory sounds and a normal heart rate with no murmur. The patient’s neurological examination, limited by the above symptoms, was otherwise normal.

***Laboratory examinations***

Routine laboratory studies, including blood glucose, hepatic and renal function, coagulation testing, glycosylated hemoglobin, autoantibodies, autoantibody spectrum associated with anti-cardiolipin antibodies, thyroid function, homocysteine, serum tumor markers, human immunodeficiency virus antibody test and syphilis spirochete hemagglutination test, were all unremarkable. The patient’s serum white cell count was 14.38 × 109/L, and her C-reactive protein level was 7 mg/L. It is worth noting that her arterial blood lactate level was 4.7 mmol/L.

***Imaging examinations***

Magnetic resonance imaging (MRI) revealed high-intensity lesions in the bitemporal lobe on T2-weighted images (Figure 1A), fluid-attenuated inversion recovery (FLAIR) (Figure 1B) images, and diffusion-weighted images (DWI) (Figure 1C and E). The parts of the lesions involving the cortex appeared hyperintense on DWI (Figure 1C) and hypointense on apparent diffusion coefficient (ADC) maps (Figure 1D), features consistent with cytotoxic edema. Follow-up brain MRI obtained on Day 27 showed an extensive reduction in FLAIR/DWI signals in the left temporal lobe (Figure 1F and G), without an apparent reduction in T2 signals.

***Electrophysiological detection***

The electroencephalogram only indicated a slight increase in fast waves.

***Further diagnostic work-up***

Magnetic resonance spectroscopy also revealed a prominent doublet and elevated lactate peak with reduced N-acetyl-aspartate levels (Figure 2). Cerebrospinal fluid (CSF) showed a white cell count of 4/μL and a protein level of 0.668 g/L with a CSF pressure of 140 mmH2O.

**FINAL DIAGNOSIS**

The mitochondrial DNA (mtDNA) 3243A>G mutation detected in the patient’s blood led to the final diagnosis of MELAS syndrome.

**TREATMENT**

The patient was initially misdiagnosed with autoimmune encephalitis and treated with gamma globulin (18 mg/d × 5 d) therapy and intravenous methylprednisolone (1000 mg/d × 3 d to 500 mg/d × 3 d to 60 mg/d × 9 d). Then, the patient was discharged with slowly tapered oral methylprednisolone (44 mg/d × 2 wk followed by a dosage reduction of 4 mg every 2 wk). When the diagnosis of MELAS was confirmed by the presence of the 3243A>G mutation (Figure 3), we immediately stopped intravenous methylprednisolone and started therapy with L-carnitine (oral 1 g/d × 8 d), L-arginine (oral 4.5 g/d × 8 d), and coenzyme Q10 (oral 60 mg/d × 8 d) (Figure 4).

**OUTCOME AND FOLLOW-UP**

The patient gradually improved before being discharged from the hospital. At the outpatient follow-up a few months later, the patient's cognitive function had recovered well, and she was basically able to take care of herself.

**DISCUSSION**

Based on some classic features of MELAS syndrome, such as repeated headaches, previous history of hearing impairment, lactic acidosis, peak lactic acid on brain MRI, and the m.3243A>G mutation detected in serum, the diagnosis of MELAS was clear in our case. The clinical presentation of MELAS depends on the existence of heteroplasmy[6], which refers to the ratio of mutant to normal mtDNA, divided into four different transcription stages of 0%, 20%-30%, 50%-90%, and 100%[7]. It is generally believed that the heteroplasmy rate of typical MELAS is 50%-90%, with higher heterogeneity being associated with earlier onset time. The age of MELAS patients is mostly 10-30 years, and there are few reports of MELAS syndrome onset after 40 years of age[1,8-10]. Our patient’s late age of onset and some other atypical symptoms were related to the low heteroplasmy.

This case initially appeared to be autoimmune encephalitis. Few cases of MELAS appearing as acute encephalitis have been reported[11-15]. Most of these cases appear to be herpes simplex encephalitis (HSE). Johns *et al*[11] described three cases with different onset symptoms, all of which involved 3243A>G mutations and increased serum lactic acid levels. The intracranial lesions in all three patients were located in the unilateral temporal or parietal lobes. The case reported by Sharfstein *et al*[12] was characterized by aphasia and delirium; the lesions were located in the left temporal and parietal lobes, and the patient carried the 3243A>G mutation. Hsu *et al*[13] described a patient with acute-onset pyrexia, headache, and seizures who showed aberrant pleocytosis in the CSF but no obvious abnormalities on MRI. The lesions described by both Gieraerts *et al*[14] and Caldarazzo Ienco *et al*[16] were bilateral, but in the study by Gieraerts *et al*[14], the lesions were widely distributed; in the study by Caldarazzo Ienco *et al*[16], they were confined to the bilateral temporal lobes. All of the cases in these abovementioned studies were characterized by the mitochondrial 3243A>G mutation. Of note, 80% of MELAS patients carry the m.3243A>G mutation in the MT-TL1 gene, whereas the frequency of this mutation in the general population is approximately 1:15000[17]. Diseases related to other types of mutations are also misdiagnosed as encephalitis in approximately 20% of MELAS patients. Yokota *et al*[15] described a patient with the mtDNA 14453G→A mutation and acute cognitive impairment, psychosis, headache, and pyrexia who showed mild pleocytosis in the CSF and a lesion in the right temporoparietal lobe.

Based on the above cases, the distribution of lesions in MELAS syndrome patients can be diverse, and the symmetry of MELAS lesions is becoming gradually recognized[18,19]. However, the signal distribution of MELAS lesions on DWI and ADC is relatively unique, especially when compared with ischemic stroke lesions. MELAS lesions most often occur due to vasogenic edema; thus, the signal intensity on ADC maps is not or only mildly reduced[20,21]. In contrast, ischemic areas are primarily caused by cytotoxic edema and generally present as restricted diffusion and low signals on ADC maps[22,23]. This phenomenon is consistent with the imaging in our case.

HSE was not the first diagnosis we considered for our patient. First, the patient’s CSF was normal, and the gold standard for diagnosing HSE was not detected. Second, the lesions in the bilateral temporal lobes on brain MRI reduced the likelihood of HSE[24,25], though the negative results for the presence of antibodies against neuronal surface antigens in the CSF could not rule out the possibility of autoimmune encephalitis. Graus *et al*[26] reported clinical diagnostic criteria for autoimmune encephalitis and specifically pointed out that mitochondrial diseases can result in a diagnosis different from autoimmune encephalitis. When the present patient visited one of our physicians, we accepted the original diagnosis of autoimmune encephalitis and discharged her. When she subsequently developed deteriorated mental status under normal medication, combined with the findings of magnetic resonance spectroscopy and serum lactic acid, we then considered the possibility of metabolic disorders, especially MELAS. The final diagnosis of our patient was confirmed by molecular genetic testing of mitochondrial DNA. This case highlights the importance of deferring a diagnosis of autoimmune encephalitis until alternative causes, including MELAS syndrome, have been excluded, especially in antibody-negative encephalitis. It should be recognized that some atypical clinical symptoms of MELAS, such as onset at an advanced age, and deviation from the classic brain MRI features, including symmetry of the lesion location, are being increasingly reported. In particular, when a disease cannot be clearly diagnosed, we should decisively turn our attention to patient characteristics that do not conform to “classic” features.

**CONCLUSION**

This case shows that late-onset MELAS syndrome is rare but should be carefully considered in patients presenting with relevant symptoms as a crucial step in the diagnosis and treatment of such patients.

**ACKNOWLEDGEMENTS**

The authors acknowledge the medical staff at Affiliated Jinhua Hospital, Zhejiang University School of Medicine for their dedicated care of the patient and the cooperation. We sincerely thank the patient.

**REFERENCES**

1 **Sproule DM**, Kaufmann P. Mitochondrial encephalopathy, lactic acidosis, and strokelike episodes: basic concepts, clinical phenotype, and therapeutic management of MELAS syndrome. *Ann N Y Acad Sci* 2008; **1142**: 133-158 [PMID: 18990125 DOI: 10.1196/annals.1444.011]

2 **Deschauer M**, Tennant S, Rokicka A, He L, Kraya T, Turnbull DM, Zierz S, Taylor RW. MELAS associated with mutations in the POLG1 gene. *Neurology* 2007; **68**: 1741-1742 [PMID: 17502560 DOI: 10.1212/01.wnl.0000261929.92478.3e]

3 **Goto Y**, Horai S, Matsuoka T, Koga Y, Nihei K, Kobayashi M, Nonaka I. Mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes (MELAS): a correlative study of the clinical features and mitochondrial DNA mutation. *Neurology* 1992; **42**: 545-550 [PMID: 1549215 DOI: 10.1212/wnl.42.3.545]

4 **McFarland R**, Taylor RW, Turnbull DM. A neurological perspective on mitochondrial disease. *Lancet Neurol* 2010; **9**: 829-840 [PMID: 20650404 DOI: 10.1016/S1474-4422(10)70116-2]

5 **Hirano M**, Pavlakis SG. Mitochondrial myopathy, encephalopathy, lactic acidosis, and strokelike episodes (MELAS): current concepts. *J Child Neurol* 1994; **9**: 4-13 [PMID: 8151079 DOI: 10.1177/088307389400900102]

6 **Crimmins D**, Morris JG, Walker GL, Sue CM, Byrne E, Stevens S, Jean-Francis B, Yiannikas C, Pamphlett R. Mitochondrial encephalomyopathy: variable clinical expression within a single kindred. *J Neurol Neurosurg Psychiatry* 1993; **56**: 900-905 [PMID: 8350109 DOI: 10.1136/jnnp.56.8.900]

7 **Picard M**, Zhang J, Hancock S, Derbeneva O, Golhar R, Golik P, O'Hearn S, Levy S, Potluri P, Lvova M, Davila A, Lin CS, Perin JC, Rappaport EF, Hakonarson H, Trounce IA, Procaccio V, Wallace DC. Progressive increase in mtDNA 3243A>G heteroplasmy causes abrupt transcriptional reprogramming. *Proc Natl Acad Sci U S A* 2014; **111**: E4033-E4042 [PMID: 25192935 DOI: 10.1073/pnas.1414028111]

8 **Zhang Z**, Zhao D, Zhang X, Xiong H, Bao X, Yuan Y, Wang Z. Survival analysis of a cohort of Chinese patients with mitochondrial encephalomyopathy with lactic acidosis and stroke-like episodes (MELAS) based on clinical features. *J Neurol Sci* 2018; **385**: 151-155 [PMID: 29406897 DOI: 10.1016/j.jns.2017.12.033]

9 **Kaufmann P**, Engelstad K, Wei Y, Kulikova R, Oskoui M, Sproule DM, Battista V, Koenigsberger DY, Pascual JM, Shanske S, Sano M, Mao X, Hirano M, Shungu DC, Dimauro S, De Vivo DC. Natural history of MELAS associated with mitochondrial DNA m.3243A>G genotype. *Neurology* 2011; **77**: 1965-1971 [PMID: 22094475 DOI: 10.1212/WNL.0b013e31823a0c7f]

10 **Yatsuga S**, Povalko N, Nishioka J, Katayama K, Kakimoto N, Matsuishi T, Kakuma T, Koga Y; Taro Matsuoka for MELAS Study Group in Japan. MELAS: a nationwide prospective cohort study of 96 patients in Japan. *Biochim Biophys Acta* 2012; **1820**: 619-624 [PMID: 21443929 DOI: 10.1016/j.bbagen.2011.03.015]

11 **Johns DR**, Stein AG, Wityk R. MELAS syndrome masquerading as herpes simplex encephalitis. *Neurology* 1993; **43**: 2471-2473 [PMID: 8255441 DOI: 10.1212/wnl.43.12.2471]

12 **Sharfstein SR**, Gordon MF, Libman RB, Malkin ES. Adult-onset MELAS presenting as herpes encephalitis. *Arch Neurol* 1999; **56**: 241-243 [PMID: 10025431 DOI: 10.1001/archneur.56.2.241]

13 **Hsu YC**, Yang FC, Perng CL, Tso AC, Wong LJ, Hsu CH. Adult-onset of mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes (MELAS) syndrome presenting as acute meningoencephalitis: a case report. *J Emerg Med* 2012; **43**: e163-e166 [PMID: 20036095 DOI: 10.1016/j.jemermed.2009.10.021]

14 **Gieraerts C**, Demaerel P, Van Damme P, Wilms G. Mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS) syndrome mimicking herpes simplex encephalitis on imaging studies. *J Comput Assist Tomogr* 2013; **37**: 279-281 [PMID: 23493219 DOI: 10.1097/RCT.0b013e3182811170]

15 **Yokota Y**, Hara M, Akimoto T, Mizoguchi T, Goto YI, Nishino I, Kamei S, Nakajima H. Late-onset MELAS syndrome with mtDNA 14453G→A mutation masquerading as an acute encephalitis: a case report. *BMC Neurol* 2020; **20**: 247 [PMID: 32552696 DOI: 10.1186/s12883-020-01818-w]

16 **Caldarazzo Ienco E**, Orsucci D, Simoncini C, Montano V, LoGerfo A, Siciliano G, Bonuccelli U, Mancuso M. Acute encephalopathy of the temporal lobes leading to m.3243A>G. When MELAS is not always MELAS. *Mitochondrion* 2016; **30**: 148-150 [PMID: 27453332 DOI: 10.1016/j.mito.2016.07.008]

17 **Goodfellow JA**, Dani K, Stewart W, Santosh C, McLean J, Mulhern S, Razvi S. Mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes: an important cause of stroke in young people. *Postgrad Med J* 2012; **88**: 326-334 [PMID: 22328278 DOI: 10.1136/postgradmedj-2011-130326]

18 **Miyahara H**, Matsumoto S, Mokuno K, Dei R, Akagi A, Mimuro M, Iwasaki Y, Yoshida M. Autopsied case with MERRF/MELAS overlap syndrome accompanied by stroke-like episodes localized to the precentral gyrus. *Neuropathology* 2019; **39**: 212-217 [PMID: 30972844 DOI: 10.1111/neup.12551]

19 **Bhatia KD**, Krishnan P, Kortman H, Klostranec J, Krings T. Acute Cortical Lesions in MELAS Syndrome: Anatomic Distribution, Symmetry, and Evolution. *AJNR Am J Neuroradiol* 2020; **41**: 167-173 [PMID: 31806591 DOI: 10.3174/ajnr.A6325]

20 **Geberhiwot T**, Chakrapani A, Hendriksz C. Case 36-2005: a woman with seizure, disturbed gait, and altered mental status. *N Engl J Med* 2006; **354**: 1096-7; author reply 1096-7 [PMID: 16525154 DOI: 10.1056/NEJMc053506]

21 **Farrar MA**, Lin CS, Krishnan AV, Park SB, Andrews PI, Kiernan MC. Acute, reversible axonal energy failure during stroke-like episodes in MELAS. *Pediatrics* 2010; **126**: e734-e739 [PMID: 20679297 DOI: 10.1542/peds.2009-2930]

22 **Tzoulis C**, Bindoff LA. Serial diffusion imaging in a case of mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes. *Stroke* 2009; **40**: e15-e17 [PMID: 19095975 DOI: 10.1161/STROKEAHA.108.523118]

23 **Xu W**, Wen J, Sun C, Cao J, Li Y, Geng D. Conventional and Diffusional Magnetic Resonance Imaging Features of Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-Like Episodes in Chinese Patients: A Study of 40 Cases. *J Comput Assist Tomogr* 2018; **42**: 510-516 [PMID: 29369945 DOI: 10.1097/RCT.0000000000000712]

24 **Pauli W**, Zarzycki A, Krzyształowski A, Walecka A. CT and MRI imaging of the brain in MELAS syndrome. *Pol J Radiol* 2013; **78**: 61-65 [PMID: 24115962 DOI: 10.12659/PJR.884010]

25 **Chow FC**, Glaser CA, Sheriff H, Xia D, Messenger S, Whitley R, Venkatesan A. Use of clinical and neuroimaging characteristics to distinguish temporal lobe herpes simplex encephalitis from its mimics. *Clin Infect Dis* 2015; **60**: 1377-1383 [PMID: 25637586 DOI: 10.1093/cid/civ051]

26 **Graus F**, Titulaer MJ, Balu R, Benseler S, Bien CG, Cellucci T, Cortese I, Dale RC, Gelfand JM, Geschwind M, Glaser CA, Honnorat J, Höftberger R, Iizuka T, Irani SR, Lancaster E, Leypoldt F, Prüss H, Rae-Grant A, Reindl M, Rosenfeld MR, Rostásy K, Saiz A, Venkatesan A, Vincent A, Wandinger KP, Waters P, Dalmau J. A clinical approach to diagnosis of autoimmune encephalitis. *Lancet Neurol* 2016; **15**: 391-404 [PMID: 26906964 DOI: 10.1016/S1474-4422(15)00401-9]

**Footnotes**

**Informed consent statement:** The written informed consent has been obtained from the patient for publication of this case report and any accompanying images.

**Conflict-of-interest statement:** The authors declare that they have no competing interests.

**CARE Checklist (2016) statement:** The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Unsolicited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Peer-review started:** January 3, 2023

**First decision:** January 30, 2023

**Article in press:**

**Specialty type:** Clinical neurology

**Country/Territory of origin:** China

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): B


Grade C (Good): C

Grade D (Fair): D


Grade E (Poor): 0

**P-Reviewer:** Mathieu C, France; Sijens PE, Netherlands; Vyshka G, Albania **S-Editor:** Yan JP **L-Editor:** A **P-Editor:**


**Figure Legends**




**Figure 1 Brain magnetic resonance imaging, fluid-attenuated inversion recovery images, diffusion-weighted images, an****d apparent diffusion coefficient maps.**A and E:Brain magnetic resonance imaging (MRI) revealed high-intensity lesions in the bitemporal lobe on T2-weighted images; B and F: Fluid-attenuated inversion recovery (FLAIR) images; C, D, G and H: Diffusion-weighted images (DWI) (C and G). The parts of the lesions involving the cortex appeared hyperintense on DWI (C and G) and hypointense on apparent diffusion coefficient maps (D and H), which is consistent with cytotoxic edema. The follow-up brain MRI obtained on day 27 showed extensive reduction FLAIR/DWI signals in the left temporal lobe, without an apparent reduction in T2 signals. T2: T2-weighted images; FLAIR: Fluid-attenuated inversion recovery images; DWI: Diffusion-weighted images; ADC: Apparent diffusion coefficient.



**Figure 2 Brain magnetic resonance spectroscopy image, with a visible lip peak in the lesion area, a significantly increased lactate peak, and a decreased NAA peak.**



**Figure 3 Results of the mitochondrial encephalomyopathy with lactic acidosis and stroke-like episodes mutation blood test.**



**Figure 4 The timeline of the patient's clinical course.** CT: Computed tomography; MRI: Magnetic resonance imaging; EEG: Electroencephalogram; CSF: Cerebrospinal fluid; MRS: Magnetic resonance spectroscopy; MELAS: Mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes.